JPWO2021133886A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021133886A5
JPWO2021133886A5 JP2022538706A JP2022538706A JPWO2021133886A5 JP WO2021133886 A5 JPWO2021133886 A5 JP WO2021133886A5 JP 2022538706 A JP2022538706 A JP 2022538706A JP 2022538706 A JP2022538706 A JP 2022538706A JP WO2021133886 A5 JPWO2021133886 A5 JP WO2021133886A5
Authority
JP
Japan
Prior art keywords
cdk
administering
inhibitor
patient
need
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022538706A
Other languages
Japanese (ja)
Other versions
JP2023508357A (en
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/066798 external-priority patent/WO2021133886A1/en
Publication of JP2023508357A publication Critical patent/JP2023508357A/en
Publication of JPWO2021133886A5 publication Critical patent/JPWO2021133886A5/ja
Pending legal-status Critical Current

Links

Claims (1)

癌治療を必要としている患者において癌を治療する方法であって、エストロゲン受容体（ＥＲ）分解剤及びサイクリン依存性キナーゼ（ＣＤＫ）阻害剤を投与することを含む、方法。 A method of treating cancer in a patient in need of cancer treatment, the method comprising administering an estrogen receptor (ER) degrading agent and a cyclin dependent kinase (CDK) inhibitor.
JP2022538706A 2019-12-23 2020-12-23 Cancer therapeutic combinations of estrogen receptor degrading agents and cyclin dependent kinase inhibitors Pending JP2023508357A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962952695P 2019-12-23 2019-12-23
US62/952,695 2019-12-23
PCT/US2020/066798 WO2021133886A1 (en) 2019-12-23 2020-12-23 Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer

Publications (2)

Publication Number Publication Date
JP2023508357A JP2023508357A (en) 2023-03-02
JPWO2021133886A5 true JPWO2021133886A5 (en) 2024-02-01

Family

ID=76575087

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022538706A Pending JP2023508357A (en) 2019-12-23 2020-12-23 Cancer therapeutic combinations of estrogen receptor degrading agents and cyclin dependent kinase inhibitors

Country Status (6)

Country Link
US (1) US11642342B2 (en)
EP (1) EP4081518A4 (en)
JP (1) JP2023508357A (en)
CN (1) CN116234803A (en)
CA (1) CA3161892A1 (en)
WO (1) WO2021133886A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022217010A1 (en) * 2021-04-09 2022-10-13 Endotarget Inc. Compounds and methods for the targeted degradation of estrogen receptors
EP4378936A1 (en) * 2021-07-30 2024-06-05 Hinova Pharmaceuticals Inc. Bifunctional chimeric heterocyclic compound and use thereof as androgen receptor degrader
CN116239566A (en) * 2021-12-08 2023-06-09 标新生物医药科技(上海)有限公司 E3 ubiquitin ligase ligand compound, protein degradation agent developed based on ligand compound and application thereof
CN117229286A (en) * 2022-06-14 2023-12-15 海创药业股份有限公司 Aromatic compound, preparation method thereof and application thereof in preparation of estrogen receptor degradation agent
WO2024015409A1 (en) * 2022-07-12 2024-01-18 Regents Of The University Of Michigan Chroman derivatives as estrogen receptor degraders
WO2024115680A1 (en) 2022-12-01 2024-06-06 Krka, D.D., Novo Mesto Ribociclib salts and formulations thereof
CN116751186A (en) * 2022-12-23 2023-09-15 南京知和医药科技有限公司 Preparation and application of estrogen receptor modulator

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010021710A1 (en) 1996-10-28 2001-09-13 Poul Jacobsen Novel cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
TW593256B (en) 1999-11-16 2004-06-21 Hormos Medical Oy Ltd Triphenylalkene derivatives and their use as selective estrogen receptor modulators
JP2001306582A (en) 2000-04-20 2001-11-02 Ge Plastics Japan Ltd Retrieval system for molded product information
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
WO2003063859A1 (en) 2002-01-14 2003-08-07 Nordic Bioscience A/S Suppression of cartilage degradation via the estrogen receptor
AU2003292625B2 (en) 2002-12-26 2008-07-24 Eisai R & D Management Co., Ltd. Selective estrogen receptor modulators
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
GB0317466D0 (en) 2003-07-25 2003-08-27 Univ Sheffield Use
ATE521341T1 (en) 2003-12-01 2011-09-15 Kudos Pharm Ltd DNA DAMAGE REPAIR INHIBITORS FOR TREATING CANCER
TWI404716B (en) 2006-10-17 2013-08-11 Kudos Pharm Ltd Phthalazinone derivative
AU2008343932B2 (en) 2007-12-19 2013-08-15 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
PT2331547E (en) 2008-08-22 2014-10-29 Novartis Ag Pyrrolopyrimidine compounds as cdk inhibitors
JP5524220B2 (en) 2008-10-07 2014-06-18 アストラゼネカ・ユーケイ・リミテッド Pharmaceutical formulation 514
JO2885B1 (en) 2008-12-22 2015-03-15 ايلي ليلي اند كومباني Protein kinase inhibitors
UA114856C2 (en) 2010-02-11 2017-08-10 Селджин Корпорейшн METHODS OF TREATMENT WITH THE APPLICATION OF ARYLMETOXISOINDOLINE DERIVATIVES
MX2012011912A (en) 2010-04-13 2012-11-16 Novartis Ag Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor and an mtor inhibitor for treating cancer.
CN102584687A (en) 2011-12-30 2012-07-18 北京赛林泰医药技术有限公司 Ethylene derivatives used as selective estrogen receptor modulators
JP2015504049A (en) 2011-12-30 2015-02-05 センタウルス・バイオファーマ・カンパニー・リミテッドＣｅｎｔａｕｒｕｓ Ｂｉｏｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． Novel aryl alkene derivatives and their use in selective estrogen receptor modulators
WO2014144740A2 (en) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Highly active anti-neoplastic and anti-proliferative agents
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
JP2019525955A (en) 2016-07-12 2019-09-12 アキュター バイオテクノロジー インコーポレイテッド Novel compounds and uses thereof
KR102173464B1 (en) * 2016-12-01 2020-11-04 아비나스 오퍼레이션스, 인코포레이티드 Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
WO2018231859A1 (en) * 2017-06-12 2018-12-20 Syros Pharmaceuticals, Inc. Compositions and methods for treating cancers with covalent inhibitors of cyclin-dependent kinase 7 (cdk7)
US10519136B2 (en) 2017-12-29 2019-12-31 Accutar Biotechnology Dual inhibitors of PARP1 and CDK
CA3096790C (en) 2018-04-09 2024-03-19 Shanghaitech University Target protein degradation compounds, their anti-tumor use, their intermediates and use of intermediates
WO2019241231A1 (en) 2018-06-11 2019-12-19 Abhishek Sharma Antiestrogen compounds
CN111205282B (en) 2018-11-21 2023-12-01 上海科技大学 ER protein modulators and uses thereof
CN113164409B (en) 2018-11-21 2023-07-18 冰洲石生物科技公司 Compounds having estrogen receptor alpha degrading activity and uses thereof
KR20210136973A (en) * 2019-01-03 2021-11-17 더 리젠츠 오브 더 유니버시티 오브 미시간 estrogen receptor proteolytic agent
WO2021118629A1 (en) 2019-12-12 2021-06-17 Accutar Biotechnology Inc. Novel chroman derivatives having estrogen receptor degradation activity and uses thereof

Similar Documents

Publication Publication Date Title
JP2022022264A5 (en)
NO20066056L (en) Treatment with Gemcitabine and an EGFR inhibitor
NO20061325L (en) Combination of drugs for the treatment of neoplasms
NO20050528L (en) Combination of VEGF receptor tyrosine kinase inhibitors for the treatment of cancer
HUP0104669A2 (en) Combination therapy of radiation and a cox-2 inhibitor for the treatment of neoplasia
JPWO2021133886A5 (en)
WO2004039325A3 (en) Treatment of pain with jnk inhibitors
JP2006502132A5 (en)
NO20031409D0 (en) Ion strength independent long-release pharmaceutical preparations
Jeung et al. Cases that respond to oncothermia monotherapy
JP2003528919A5 (en)
de Ligt et al. The angiotensin II type 1 receptor blocker valsartan in the battle against COVID‐19
NO20064753L (en) combination therapy
WO2010045522A3 (en) Combination therapies for the treatment of obesity
NO20042758L (en) Procedure for treating a patient requiring analgesia.
JP2007536359A5 (en)
Lyu et al. Role and mechanism of DNA methylation and its inhibitors in hepatic fibrosis
MD2549F1 (en) Method of treatment of the chronic viral hepatitis C
SE0102887D0 (en) New formulation
Jin et al. Apatinib monotherapy for advanced VEGFR-2-negative nasopharyngeal carcinoma: A case report
JP2004521140A5 (en)
Yu et al. Chromoblastomycosis successfully treated with fluconazole.
Shetty et al. Effectiveness of physiotherapy rehabilitation on hysterical trismus
Basu et al. Is interferon-α and retinoic acid combination along with radiation superior to chemo-radiation in the treatment of advanced carcinoma of cervix?
DE50214008D1 (en) MEDICAMENT FOR THE TREATMENT OF TUMORS AND THEIR METASTASES USING A BINDING MOLECULE AGAINST THE BONE SIALOPROTEIN